Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Metabolic Pharmaceuticals ultimately did not pursue Phase 3 trials for obesity, and the company's pipeline shifted toward other indications
A second oral GLP-1 approval is anticipated in the first half of 2026 from Eli Lilly with orforglipron
Previously, the ACHIEVE-1 study evaluated orforglipron monotherapy in people with early type 2 diabetes uncontrolled with lifestyle intervention, and demonstrated a 12 mmol/mol (1.1%) greater HbA 1c reduction and a 5.9% greater body weight reduction than placebo (Rosenstock et al, 2025)
I tried the service myself and found the portions generous, the recipes easy to follow, and the food tasty and filled with produce
.png)
US$ 24.76
US$ 20.68
US$ 25.14
US$ 25.72
US$ 23.82
